JP2020530007A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530007A5
JP2020530007A5 JP2020506300A JP2020506300A JP2020530007A5 JP 2020530007 A5 JP2020530007 A5 JP 2020530007A5 JP 2020506300 A JP2020506300 A JP 2020506300A JP 2020506300 A JP2020506300 A JP 2020506300A JP 2020530007 A5 JP2020530007 A5 JP 2020530007A5
Authority
JP
Japan
Prior art keywords
psma
alkyl
drug composition
group
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020506300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530007A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/027106 external-priority patent/WO2018191376A2/en
Publication of JP2020530007A publication Critical patent/JP2020530007A/ja
Publication of JP2020530007A5 publication Critical patent/JP2020530007A5/ja
Priority to JP2023061616A priority Critical patent/JP2023093545A/ja
Priority to JP2024199226A priority patent/JP2025028897A/ja
Pending legal-status Critical Current

Links

JP2020506300A 2017-04-11 2018-04-11 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2−pmpaのプロドラッグ Pending JP2020530007A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023061616A JP2023093545A (ja) 2017-04-11 2023-04-05 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ
JP2024199226A JP2025028897A (ja) 2017-04-11 2024-11-14 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762484219P 2017-04-11 2017-04-11
US62/484,219 2017-04-11
PCT/US2018/027106 WO2018191376A2 (en) 2017-04-11 2018-04-11 Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023061616A Division JP2023093545A (ja) 2017-04-11 2023-04-05 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ

Publications (2)

Publication Number Publication Date
JP2020530007A JP2020530007A (ja) 2020-10-15
JP2020530007A5 true JP2020530007A5 (enExample) 2021-05-20

Family

ID=63792979

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020506300A Pending JP2020530007A (ja) 2017-04-11 2018-04-11 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2−pmpaのプロドラッグ
JP2023061616A Pending JP2023093545A (ja) 2017-04-11 2023-04-05 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ
JP2024199226A Pending JP2025028897A (ja) 2017-04-11 2024-11-14 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023061616A Pending JP2023093545A (ja) 2017-04-11 2023-04-05 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ
JP2024199226A Pending JP2025028897A (ja) 2017-04-11 2024-11-14 Psma標的化ガンイメージングまたは放射線療法中の健康組織保護のための2-pmpaのプロドラッグ

Country Status (10)

Country Link
US (1) US12508271B2 (enExample)
EP (1) EP3609544B1 (enExample)
JP (3) JP2020530007A (enExample)
KR (1) KR102686172B1 (enExample)
CN (1) CN111801121B (enExample)
AU (1) AU2018250609B2 (enExample)
ES (1) ES3021195T3 (enExample)
IL (1) IL269969B2 (enExample)
SG (1) SG11201909513QA (enExample)
WO (1) WO2018191376A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
JP7429688B2 (ja) * 2018-09-21 2024-02-08 エンドサイト・インコーポレイテッド シールド剤およびそれらの使用
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2021202376A1 (en) * 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
US20230165980A1 (en) * 2020-04-29 2023-06-01 Novartis Ag Methods for radiolabeling psma binding ligands and their kits
IL297323A (en) * 2020-04-29 2022-12-01 Novartis Ag Methods for radiological labeling of psma-binding ligands and their kits
AU2021352915A1 (en) * 2020-10-01 2023-06-08 Cornell University Methods and compositions for increasing uptake, internalization, and/or retention of small molecule ligands
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
CN113354709B (zh) * 2021-06-03 2023-06-09 江苏华益科技有限公司 一种转移性前列腺癌靶向性药物前体的固相合成方法
EP4536278A4 (en) 2022-06-07 2026-08-12 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
WO2023239903A1 (en) * 2022-06-09 2023-12-14 Case Western Reserve University Compositions and methods for preventing retention of psma-targeted therapy
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof
WO2025167998A1 (zh) * 2024-02-06 2025-08-14 北京昌平实验室 膦酸酯骨架的psma靶向偶联物
WO2026120497A1 (en) 2024-12-05 2026-06-11 Novartis Ag Stable radionuclide complex solutions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
US10172873B2 (en) * 2014-08-06 2019-01-08 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors
ES2908411T3 (es) * 2014-08-06 2022-04-29 Univ Johns Hopkins Profármacos del inhibidor del antígeno de membrana específico de la próstata (PSMA)
JP2017530109A (ja) * 2014-09-08 2017-10-12 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 前立腺癌についてのpsmaを標的とした放射性核種治療中の臓器の保護

Similar Documents

Publication Publication Date Title
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
JP2021063088A5 (enExample)
JP2019529518A5 (enExample)
JP2023179556A (ja) 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法(trt)の使用
JP2010501584A5 (enExample)
IL269969B2 (en) 2-pmpa protrope for healthy tissue protection during imaging or radiotherapy of psma-targeted cancer
AU2017302539B2 (en) Targeted radiotherapy chelates for In Situ Immune Modulated Cancer Vaccination
JP5149177B2 (ja) 増殖性疾患の治療のための、チューブリンポリマー化の1,2,3−トリアゾール系抑制剤
JP2008530240A (ja) 増殖性疾患の治療のための化合物
JP2007509928A5 (enExample)
JP2009544582A5 (enExample)
JP2024544870A5 (enExample)
JP2019011381A5 (enExample)
JP2021534160A5 (enExample)
RU2007145489A (ru) Фармацевтические композиции и способы лечения рака и его метастазов
JP2016515615A5 (enExample)
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
US20190184021A1 (en) Porphyrin Compounds and Compositions Useful for Treating Cancer
JP2016514160A5 (enExample)
JP2006517195A5 (enExample)
Patterson et al. Combretastatin A-4 phosphate
JPWO2019244954A1 (ja) ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン10薬剤
AU2020341213B2 (en) Pharmaceutical composition comprising HDAC inhibitor and anti-PD1 antibody or anti PD-L1 antibody
RU2019104928A (ru) Производное индола, используемое в качестве ингибитора CRTH2
JP5322651B2 (ja) シンチグラフィー法